BMS Builds Onto HIV Franchise With Once-daily NRTI From Japanese Biotech Oncolys BioPharma
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Bristol-Myers Squibb continues to build up its HIV franchise, obtaining global rights for a nucleoside reverse transcriptase inhibitor from Japanese biotech Oncolys BioPharma
You may also be interested in...
Abbott, Baxter, Bristol-Myers Squibb: Emerging Markets Earnings Roundup (Part 1 of 3)
A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources in Asia and forming more Asia partnerships. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).